PURPOSE: The goal of the present study was to analyze prognostic factors in patients treated with external-beam radiation therapy (EBRT), surgical resection and intraoperative electron-beam radiotherapy (IOERT) for oligorecurrent gynecological cancer (ORGC). PATIENTS AND METHODS: From January 1995 to December 2012, 61 patients with ORGC [uterine cervix (52 %), endometrial (30 %), ovarian (15 %), vagina (3 %)] underwent IOERT (12.5 Gy, range 10-15 Gy), and surgical resection to the pelvic (57 %) and paraaortic (43 %) recurrence tumor bed. In addition, 29 patients (48 %) also received EBRT (range 30.6-50.4 Gy). Survival outcomes were estimated using the Kaplan-Meier method, and risk factors were identified by univariate and multivariate analyses. RESULTS: Median follow-up time for the entire cohort of patients was 42 months (range 2-169 months). The 10-year rates for overall survival (OS) and locoregional control (LRC) were 17 and 65 %, respectively. On multivariate analysis, no tumor fragmentation (HR 0.22; p = 0.03), time interval from primary tumor diagnosis to locoregional recurrence (LRR) < 24 months (HR 4.02; p = 0.02) and no EBRT at the time of pelvic recurrence (HR 3.95; p = 0.02) retained significance with regard to LRR. Time interval from primary tumor to LRR < 24 months (HR 2.32; p = 0.02) and no EBRT at the time of pelvic recurrence (HR 3.77; p = 0.04) showed a significant association with OS after adjustment for other covariates. CONCLUSION: External-beam radiation therapy at the time of pelvic recurrence, time interval for relapse ≥ 24 months and not multi-involved fragmented resection specimens are associated with improved LRC in patients with ORGC. As suggested from the present analysis a significant group of ORGC patients could potentially benefit from multimodality rescue treatment.
PURPOSE: The goal of the present study was to analyze prognostic factors in patients treated with external-beam radiation therapy (EBRT), surgical resection and intraoperative electron-beam radiotherapy (IOERT) for oligorecurrent gynecological cancer (ORGC). PATIENTS AND METHODS: From January 1995 to December 2012, 61 patients with ORGC [uterine cervix (52 %), endometrial (30 %), ovarian (15 %), vagina (3 %)] underwent IOERT (12.5 Gy, range 10-15 Gy), and surgical resection to the pelvic (57 %) and paraaortic (43 %) recurrence tumor bed. In addition, 29 patients (48 %) also received EBRT (range 30.6-50.4 Gy). Survival outcomes were estimated using the Kaplan-Meier method, and risk factors were identified by univariate and multivariate analyses. RESULTS: Median follow-up time for the entire cohort of patients was 42 months (range 2-169 months). The 10-year rates for overall survival (OS) and locoregional control (LRC) were 17 and 65 %, respectively. On multivariate analysis, no tumor fragmentation (HR 0.22; p = 0.03), time interval from primary tumor diagnosis to locoregional recurrence (LRR) < 24 months (HR 4.02; p = 0.02) and no EBRT at the time of pelvic recurrence (HR 3.95; p = 0.02) retained significance with regard to LRR. Time interval from primary tumor to LRR < 24 months (HR 2.32; p = 0.02) and no EBRT at the time of pelvic recurrence (HR 3.77; p = 0.04) showed a significant association with OS after adjustment for other covariates. CONCLUSION: External-beam radiation therapy at the time of pelvic recurrence, time interval for relapse ≥ 24 months and not multi-involved fragmented resection specimens are associated with improved LRC in patients with ORGC. As suggested from the present analysis a significant group of ORGC patients could potentially benefit from multimodality rescue treatment.
Authors: M A Mahé; J P Gérard; J B Dubois; A Roussel; E Bussières; M Delannes; F Guillemin; T Schmitt; D Dargent; Y Guillard; P Martel; P Richaud; J C Cuillière; J De Ranieri; L Malissard Journal: Int J Radiat Oncol Biol Phys Date: 1996-01-01 Impact factor: 7.038
Authors: Anurag K Singh; Perry W Grigsby; Janet S Rader; David G Mutch; Matthew A Powell Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: Sean C Dowdy; Andrea Mariani; William A Cliby; Michael G Haddock; Ivy A Petersen; Franklin H Sim; Karl C Podratz Journal: Gynecol Oncol Date: 2006-05 Impact factor: 5.482
Authors: C A Perez; R R Kuske; H M Camel; A E Galakatos; M A Hederman; M S Kao; B J Walz Journal: Int J Radiat Oncol Biol Phys Date: 1988-04 Impact factor: 7.038
Authors: M L Gemignani; K M Alektiar; M Leitao; B Mychalczak; D Chi; E Venkatraman; R R Barakat; J P Curtin Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-01 Impact factor: 7.038
Authors: G R Garton; L L Gunderson; M J Webb; T O Wilson; S S Cha; K C Podratz Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-01 Impact factor: 7.038
Authors: Brandon M Barney; Ivy A Petersen; Sean C Dowdy; Jamie N Bakkum-Gamez; Kristi A Klein; Michael G Haddock Journal: Radiat Oncol Date: 2013-04-08 Impact factor: 3.481
Authors: Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Javier Pascau; Hugo Marsiglia Journal: Strahlenther Onkol Date: 2014-06-14 Impact factor: 3.621
Authors: Claudio V Sole; Felipe A Calvo; Pedro Alvarez de Sierra; Rafael Herranz; Luis Gonzalez-Bayon; Jose Luis García-Sabrido Journal: J Cancer Res Clin Oncol Date: 2014-04-10 Impact factor: 4.553
Authors: L G P H Vroomen; H J Scheffer; M C A M Melenhorst; N van Grieken; M P van den Tol; M R Meijerink Journal: Cardiovasc Intervent Radiol Date: 2017-05-03 Impact factor: 2.740